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A B S T R A C T
Background
In some women, an episode of preterm labour settles and does not result in immediate preterm birth. Subsequent treatment with
tocolytic agents such as oxytocin receptor antagonistsmay then have the potential to prevent the recurrence of preterm labour, prolonging
gestation, and preventing the adverse consequences of prematurity for the infant.
Objectives
To assess the effects of maintenance therapy with oxytocin antagonists administered by any route after an episode of preterm labour in
order to delay or prevent preterm birth.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 July 2013), sought ongoing and unpublished trials
by contacting experts in the field and searched the reference lists of relevant articles.
Selection criteria
Randomised controlled trials comparing oxytocin antagonists with any alternative tocolytic agent, placebo or no treatment, used for
maintenance therapy after an episode of preterm labour.
Data collection and analysis
Weused the standard methods of The Cochrane Collaboration and the Cochrane Pregnancy and Childbirth Group. Two review authors
independently undertook evaluation of methodological quality and extracted trial data.
Main results
This review includes one trial of 513 women. When compared with placebo, atosiban did not reduce preterm birth before 37 weeks
(risk ratio (RR) 0.89; 95% confidence intervals (CI) 0.71 to 1.12), 32 weeks (RR 0.85; 95% CI 0.47 to 1.55), or 28 weeks (RR 0.75;
95% CI 0.28 to 2.01). No difference was shown in neonatal morbidity, or perinatal mortality.
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Authors’ conclusions
There is insufficient evidence to support the use of oxytocin receptor antagonists to inhibit preterm birth after a period of threatened
or actual preterm labour. Any future trials using oxytocin antagonists or other drugs as maintenance therapy for preventing preterm
birth should examine a variety of important infant outcome measures, including reduction of neonatal morbidity and mortality, and
long-term infant follow-up. Future research should also focus on the pathophysiological pathways that precede preterm labour.
P L A I N L A N G U A G E S U M M A R Y
Oxytocin Antagonists for suppressing preterm birth after an episode of preterm labour
Preterm labour is indicated by regular contractions of the uterus and changes in the cervix (the opening of the womb) before 37 weeks
of pregnancy. Preterm labour and birth may be associated with illness or death of the baby, and often place a substantial emotional
burden on families. Preterm birth may also result in childhood disability. Even a short-term prolongation of pregnancy after the onset
of threatened or actual preterm labour can allow the administration of corticosteroids to the mother to hasten fetal lung maturation
and transfer of the mother to a centre with neonatal intensive care facilities. A range of drugs (tocolytic) are used to suppress labour.
The oxytocin antagonist atosiban is one of these. Once the episode of threatened preterm labour settles, maintenance treatment with
a tocolytic can then be used to try to prevent any reoccurrence. This has to be balanced against potential adverse outcomes such as
intrauterine infection, fetal death, an increase in severe disability for survivors, and side-effects of the drugs.
This review identified only one good quality multicentre controlled trial which showed that subcutaneously administered atosiban
as maintenance therapy did not reduce the incidence of preterm birth or improve neonatal outcomes when compared with placebo
treatment. The trial randomised 513 women in whom preterm labour (with intact membranes and limited cervical dilatation) ceased
following intravenous treatment with atosiban. The mean gestation at enrolment was around 31 weeks and the proportion of multiple
births was similar in the two groups. Atosiban infused at 6 mL/hr (30 µg/min) did not reduce preterm birth before 28, 32, or 37
weeks. Women on maintenance therapy were discharged home with a continuous subcutaneous infusion pump and daily nursing
contact. There was an increase in injection site reaction for the atosiban group. There is insufficient evidence of benefit to justify this
intervention.
B A C K G R O U N D
In developed countries, preterm birth, defined as birth before 37
completed weeks (WHO 2012), is the most important cause of
perinatal morbidity and mortality after congenital anomalies (
Goldenberg 2008).
Preterm birth occurring between 20 and 36 completed weeks is a
major contributor to perinatal mortality andmorbidity.More than
one in 10babies bornworldwide in 2010was bornpremature, with
an annual estimationof 15millionpretermbirths (Blencowe 2012;
WHO 2012). Preterm birth accounts for approximately 75% of
perinatal mortality and more than 50% of long-term morbidity
(Hack 1999).
Preterm birth is associated not only with high immediate costs at-
tributable to neonatal intensive care, but alsowith substantial long-
term costs, including costs for special education (Petrou 2011),
and other services for infants and children with intellectual and
physical disability (Petrou 2011). In addition to the lengthy neona-
tal intensive care treatment required for many preterm infants,
pretermbirth often constitutes amajor crisis in the lives of parents,
and places a substantial emotional burden on families (McCain
1993).
The exact causes of preterm birth are not known. Preterm labour
can be the final clinical endpoint of several distinct but converg-
ing pathophysiological pathways, including: inflammation/infec-
tion causing maternal/fetal cytokine and prostaglandin produc-
tion; maternal/fetal stress leading to endocrine changes; mechan-
ical stress due to abnormal uterine distention; or abruption (pla-
centa/decidual haemorrhage). Because there are several mecha-
nisms, which can occur independently or in combination, it is
difficult to identify universal management strategies to prevent
preterm birth. To reduce the incidence of preterm birth, a better
understanding of the complex triggers of the final common path-
way is needed.
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The incidence of preterm birth is increasing in developed and
developing countries affecting, on average, 11.8% of births in low-
income countries and 9.3% to 9.4% in upper-middle- and high-
income countries (WHO 2012).
In developed countries, the incidence of preterm birth varies
within a narrow range from 6% to 10% (Lumley 2003). This inci-
dence has not declined over the past two decades despite intensive
antenatal care programs aimed at identifying high-risk groups for
preterm birth, the widespread use of tocolytic agents, and other
preventive and therapeutic interventions.
The incidence of preterm birth is probably much higher in low-
income than high-income countries, but precise data are lacking
because of inaccurate estimation of gestation (Kramer 2003) and
registration of births (Kramer 2003; Lumley 2003). Nevertheless,
preterm delivery is one of themajor direct causes of neonatal death
in low-income countries, and is estimated to account formore than
1.1 million neonatal deaths worldwide annually (WHO 2012).
Although the incidence in preterm birth has not declined, even
short-term prolongation of pregnancy is beneficial if it enables
the administration of corticosteroids to the mother to hasten fetal
lung maturation (Roberts 2006) and/or transfer to a centre with
neonatal intensive care facilities (Powell 1995). Perinatal mortality
and morbidity is significantly reduced after administration of a
full course of corticosteroids (Roberts 2006).
A range of drugs (tocolytic) have been used to inhibit preterm
labour to allow time for such co-interventions. These drugs are
the topics of Cochrane systematic reviews including nitric ox-
ide donors (glyceryl trinitrate) (Duckitt 2002), calcium chan-
nel blockers (such as nifedipine) (King 2003), betamimetics
(Anotayanonth 2004), magnesium sulphate (Crowther 2002), cy-
clo-oxygenase (COX) inhibitors (Khanprakob 2012) and oxytocin
receptor antagonists (Papatsonis 2005).
For those women with preterm labour who are treated with to-
colytics and remain undelivered after 48 hours, maintenance treat-
ment with a tocolytic is sometimes used to further delay delivery
and to prolong pregnancy. Maintenance treatment regimens of
differing duration, and using a number of different tocolytic, have
been proposed. These include betamimetics (Dodd 2012; Nanda
2002), magnesium sulphate (Han 2013), and calcium channel
blockers (Gaunekar 2004).
The potential advantages of prolonging pregnancy should be bal-
anced against potential adverse outcomes such as intrauterine in-
fection, fetal demise, and side-effects of the drugs. Prolonging
pregnancy at the border of viability could increase the short-term
survival rate, but without improving overall survival and/or at the
cost of an increase in severe disability for survivors. Therefore, the
assessment of effects of interventions to improve outcomes should
be based not only on mortality rates but also on major morbidity
including long-term outcomes.
Oxytocin antagonists (commonly atosiban) are used for tocolysis
in several countries and atosiban has been registered in Europe as
a tocolytic agent. This review will determine if there is sufficient
evidence to support the use of maintenance therapy with oxytocin
antagonists after an episode of threatened or actual preterm labour.
O B J E C T I V E S
To assess the efficacy and safety of maintenance treatment with
oxytocin antagonists after an episode of threatened or actual
preterm labour, in preventing pretermbirth and other adverse out-
comes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published, unpublished and ongoing randomised trials with
data from women and infants in which oxytocin receptor antago-
nists, given for maintenance treatment after an episode of preterm
labour (threatened or actual), were compared with an alternative
tocolytic agent, placebo, or no treatment. Trials that employed
quasi-random methods of treatment allocation were not eligible
for inclusion.
Types of participants
Pregnant women who had at least one episode of preterm labour
between 20 and 36 completed weeks that was suppressed or settled
spontaneously without resulting in immediate preterm birth.
For the purposes of this review, preterm labour was defined as
the presence of uterine contractions with intact or ruptured mem-
branes, with or without cervical dilation.
Types of interventions
Oxytocin antagonists administered as maintenance therapy by any
route and dose compared with either placebo, no treatment, or
alternative tocolytic therapy. Trials of women where oxytocin an-
tagonists are combined with any other tocolytic agent were not
eligible for inclusion.
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Types of outcome measures
Primary outcome measures
(1) Very preterm birth less than 32 weeks gestation.
(2) Perinatal or infant mortality or any neurological disability at
long-term paediatric follow-up at two years of age (vision impair-
ment, sensorineural deafness requiring hearing aids, cerebral palsy
or developmental delay/intellectual impairment).
Secondary outcome measures
These include other measures of effectiveness, complications of
treatment and health service use.
Maternal
(1) Serious maternal outcomes (defined as death, coma, cardiac
arrest, respiratory arrest, use of a mechanical ventilator, admission
to intensive care unit).
(2)Mild maternal side-effects (defined as not necessitating discon-
tinuation of therapy).
(3) Serious maternal side-effects necessitating discontinuation of
therapy.
(4) Antepartum haemorrhage.
(5) Postpartum haemorrhage.
(6) Prelabour rupture of the membranes before 34 weeks.
(7) Duration of antenatal and postnatal maternal hospital stay.
(8) Maternal satisfaction with treatment.
(9) Maternal quality of life after the birth (measured by validated
instruments).
Infant/child
(1) Mortality
• Perinatal mortality.
• Fetal death.
• Neonatal death.
• Infant death (death of liveborn infants up to 12 months of
age).
(2) Time to delivery
• Preterm birth within 24, 48 and 72 hours and one week of
commencing maintenance therapy.
• Randomisation to birth interval.
(3) Neonatal morbidity
• Birth less than 37 completed weeks.
• Birth less than 28 completed weeks.
• Apgar score less than seven at five minutes.
• Neonatal hypoglycaemia.
• Neonatal encephalopathy or seizures.
• Respiratory distress syndrome.
• Use of mechanical ventilation.
• Duration of mechanical ventilation.
• Persistent pulmonary hypertension of the neonate.
• Intraventricular haemorrhage.
• Periventricular leukomalacia.
• Chronic lung disease.
• Necrotising enterocolitis.
• Retinopathy of prematurity.
• Neonatal jaundice requiring phototherapy.
• Neonatal early or late onset sepsis.
• Birthweight.
• Birthweight for gestation.
• Gestation at birth.
(3) Use of health service
• Admission to a neonatal intensive care unit.
• Neonatal length of hospital stay.
• Maternal admission to intensive care unit.
• Costs associated with maintenance therapy versus no
maintenance therapy.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 July
2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
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Searching other resources
We sought ongoing and unpublished trials by contacting experts
in the field and searched the reference lists of relevant articles.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
We used the standard methods of The Cochrane Collaboration
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). Two review authors (Vicki Flenady
(VF), Dimitri Papatsonis (DP)) considered trials for inclusion in-
dependently. We resolved discrepancies by discussion including
the third review author (Helen Liley).
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors (VF, DP) extracted the data using the agreed form.
We resolved discrepancies through discussion or, if required, we
consulted the third author. We entered data into Review Manager
software (RevMan 2012), and checked for accuracy.
We contacted the authors of the published abstracts for additional
information or data (Valenzuela 2000); however, no additional
information was forthcoming.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for the in-
cluded study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We resolved
any disagreement by discussion, or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
For the included study, we describe the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For the included study, we describe the method used to conceal
allocation at the point of randomisation, and assess whether in-
tervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For the included study, we describe the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For the included study, we describe the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received.
We assessed methods used to blind outcome assessment as low,
high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For the included study, we describe the completeness of data in-
cluding attrition and exclusions from the analysis. We looked at
whether attrition and exclusions were reported, and the numbers
included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes. Where sufficient information was re-
ported, or supplied by the trial authors, we planned to re-include
missing data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
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substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For the included study, we describe how we investigated the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; or study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We describe any important concerns we have about other possible
sources of bias such as baseline imbalance between groups.
We examined whether the study was free of other problems that
could put it at risk of bias and assessed methods as:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We have made explicit judgements about whether the study is at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings. We planned
to explore the impact of the level of bias through undertaking
sensitivity analyses, but as only one study was included we did not
carry out this additional analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we present the mean difference with 95%
confidence intervals. In this version of the review we have not
pooled any findings as we included only one trial, but in updates
we will use the mean difference to combine findings from trials
provided outcomes are measured in the same way between trials.
If appropriate, we will use the standardised mean difference to
combine trials that report the same outcome,measured in different
ways.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials in this version
of the review. In future updates, if such trials are identified, we will
include them in the analyses along with individually-randomised
trials. We will adjust their sample sizes using the methods de-
scribed in the Handbook (Higgins 2011), using an estimate of the
intracluster correlation co-efficient (ICC) derived from the trial
(if possible), from a similar trial or from a study of a similar pop-
ulation. If we use ICCs from other sources, we will conduct sen-
sitivity analyses to investigate the effect of variation in the ICC.
If we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information pro-
vided there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over studies were not included; this is not a suitable design
for this type of intervention.
Other unit of analysis issues
If any multi-armed trials are identified when we update the re-
view, where appropriate, we will combine arms (using methods
described in the Handbook (Higgins 2011)) to create a single pair-
wise comparison. If it is not appropriate to combine experimental
arms we will present results separately for each arm, sharing results
for the control arm between each to avoid double counting (for
dichotomous outcomes we will divide the number of events and
total sample by two, for continuous outcomes we will assume the
same mean and standard deviation but halve the control sample
size for each comparison).
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Dealing with missing data
For the included study, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis; in this version of the review we did not carry out
any meta-analysis so we did not carry out this planned sensitivity
analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants are analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome is the number randomised
minus any participants whose outcomes are known to be missing.
Assessment of heterogeneity
If we had combined trials in meta-analysis, we planned to assess
statistical heterogeneity using the T², I² and Chi² statistics. If we
carry out meta-analysis in updates we will regard heterogeneity as
substantial if an I² is greater than 30% and either the T² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If in future updates there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager software
(RevMan 2012). If in future updates we carry out any meta-analy-
sis, we will use fixed-effectmeta-analysis for combining data where
it is reasonable to assume that studies are estimating the same un-
derlying treatment effect: i.e. where trials are examining the same
intervention, and the trials’ populations and methods are judged
to be sufficiently similar. If there is clinical heterogeneity sufficient
to expect that the underlying treatment effects differ between tri-
als, or if substantial statistical heterogeneity is detected, we will
use random-effects meta-analysis to produce an overall summary
where an average treatment effect across trials is considered clini-
cally meaningful. The random-effects summary will be treated as
the average range of possible treatment effects, and we will discuss
the clinical implications of treatment effects differing between tri-
als.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
In future updates, if sufficient data are available, we will carry out
subgroup analysis as follows:
• all women with preterm labour before 32 completed weeks
at randomisation compared with women at or beyond 32 weeks;
• dosage of oxytocin receptor antagonists;
• type of oxytocin receptor antagonists;
• duration of tocolytic therapy;
• type of tocolytic therapy comparisons.
We will examine only our primary outcomes in subgroup analysis.
We will assess subgroup differences by interaction tests available in
RevMan (RevMan 2012). We will report the results of subgroup
analyses quoting the χ2 statistic and P value, and the interaction
test I² value.
Sensitivity analysis
If we had included cluster-randomised trials in the review, we
planned to carry out sensitivity analysis. We also planned sensitiv-
ity analysis according to trial quality; temporarily excluding trials
at high risk of bias to explore whether this has any impact on the
direction or size of the effect estimate. In this version of the review
we did not carry out any sensitivity analysis as we did not carry out
any meta-analysis. If more data are included in updates, we will
carry out planned sensitivity analysis using our primary outcomes
only.
R E S U L T S
Description of studies
Three publications were identified as potentially eligible for inclu-
sion in this review. Two of the three publications (Gagnon 1998;
Sanchez-Ramos 1997) were abstracts reporting data from the only
available identified study (Valenzuela 2000).
Included studies
One study including a total of 513 women that compared mainte-
nance therapy using atosiban versus placebo to prevent recurrence
of preterm labour (Valenzuela 2000) was included in this review.
Excluded studies
There were no excluded studies.
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Participants
Gestation at inclusion ranged from 20 to 33 6/7 weeks. The mean
gestation at inclusion was 31.0 (standard deviation (SD) 2.62)
weeks for the placebo group and 30.6 (SD 2.78) weeks for the
atosiban group. Women were eligible for the study when there was
preterm labour in a pregnancy, with intact membranes and≤ 3 cm
cervical dilatation, with a live fetus, after uterine quiescence was
achieved with intravenous atosiban (not placebo) in a multicentre
trial comparing placebo or atosiban for the treatment of preterm
labour. Exclusion criteria were: fetal or placental abnormalities by
ultrasonography, maternal indications for delivery, urinary tract
infection, and overt clinical manifestations of substance abuse.
Tocolysis
The trial (Valenzuela 2000) compared atosiban with placebo,
both administered subcutaneously to women in whom preterm
labour had ceased following treatment with atosiban. Atosiban
and placebo were administered at the same volume and rate.
Atosiban group: atosiban for maintenance was administered by
a subcutaneous infusion pump to provide a continuous atosiban
infusion of 6 mL/hour (30 µg/min).
Placebo group: placebo for maintenance was administered by a
subcutaneous infusion pump to provide a continuous placebo in-
fusion of 6 mL/hour.
Both active drug and placebo were administered until the end of
week 36 of gestation, delivery, or progression of labour requiring
an alternative tocolytic agent. All women on maintenance therapy
were discharged home with daily nursing contact for all, compli-
ance was checked by diaries kept by women and records of drugs
used.
Rescue therapy with intravenous atosiban could be given for any
additional episode of preterm labour, followed by subcutaneous
maintenance therapywith the assigned study treatmentwhen uter-
ine quiescence was again achieved.
Please see table of Characteristics of included studies for further
details.
Risk of bias in included studies
Maintenance therapy atosiban versus placebo
The included trial (Valenzuela 2000) was considered of good qual-
ity with a low risk of bias for each of the bias domains assessed with
the exception of reporting bias, which had an unclear risk of bias..
The trial employed a blinded method of randomisation according
to a computer-generated schedule using pre-numbered envelopes
containing the allocation to study group provided to the pharma-
cist at each centre for use in sequential order. The randomisation
schedule was developed using permuted blocks of four and was
stratified by centre but not gestation. Blinding of the intervention
was undertaken with the use of a placebo which was identical in
appearance and administration to the atosiban arm of the trial.
One woman in the placebo group, who did not receive treat-
ment, was excluded post-randomisation. Eight participants in the
placebo group received some atosiban in error but were analysed
by intention-to-treat for the purposes of assessing efficacy.
The primary outcome variable, on which the sample size calcula-
tion was based, was the number of days from the start of mainte-
nance therapy until the recurrence of preterm labour.
Although all mothers appear accounted for in the reported out-
comes of the study, the numbers of infants referred to in the text
and tables amount to 568, 563 (272 placebo, 291 atosiban) and
558 infants (269 placebo, 289 atosiban), without further explana-
tion of the discrepancies. One of these discrepant infants is possi-
bly the single fetal death (in the atosiban group).
Further information on outcomes has been sought from the trial
investigator and will be included in future updates when available.
To date, no information has been forthcoming.
For further details see table of Characteristics of included studies.
Effects of interventions
This review included data from one study with a total of 513
women .
Compared with placebo, the use of atosiban as maintenance ther-
apy for prevention of recurrent preterm labour did not reduce the
incidence of preterm birth before 37 weeks (risk ratio (RR) 0.89;
95% confidence interval (CI) 0.71 to 1.12), 32 weeks (RR 0.85;
95% CI 0.47 to 1.55), or 28 weeks (RR 0.75; 95% CI 0.28 to
2.01). While not defined as an a priori outcome measure of this
review, the median interval from the start of maintenance therapy
to the first recurrence of labour was prolonged (32.6 days in the
atosiban group versus 27.6 days in the placebo group, P = 0.02),
as was the time to recurrence of preterm labour (36.2 versus 28.2
days, P = 0.03). The number of women who received ’rescue’ to-
colytic treatment was not significantly reduced.
Please see table 0f Characteristics of included studies for further
details.
Maternal outcomes
There were no maternal deaths reported. While the data on ma-
ternal outcomes are not reported within the total adverse events
for the study, Valenzuela 2000 state that the adverse event profiles
were comparable, and there was an increase in injection site reac-
tion for the atosiban group (RR 1.55; 95% CI 1.33 to 1.81).
Neonatal outcomes
Among the 558 infants, neonatal outcomes were similar for both
groups with respect to birthweight (mean difference (MD) 0.10;
95% CI -131.78 to 131.98) respiratory distress syndrome (RR
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1.06; 95% CI 0.66 to 1.70), patent ductus arteriosus (RR 1.17;
95% CI 0.47 to 2.91) and necrotising enterocolitis (RR 2.34; CI
95% 0.46 to 11.93). The outcomes were also reported to be simi-
lar for intraventricular haemorrhage; however, these data were not
able to be included until further clarification about the denomi-
nators is received from the authors. Neonatal intensive care unit
admissions (RR 0.84; 95%CI 0.62 to 1.14) and fetal and neonatal
deaths were similar for both groups (five in each). No long-term
infant outcomes were reported.
D I S C U S S I O N
The results of this review do not support the use of atosiban as
maintenance therapy after an episode of preterm labour. When
atosiban was compared with placebo, there was no reduction of
the incidence of preterm birth and no improvement of any re-
ported neonatal outcome. The treatment involved at least mater-
nal inconvenience (continuous subcutaneous infusion pump for
days to weeks) and although there was no excess of severe maternal
side-effects, the incidence of maternal injection site reactions was
significantly higher among women treated with atosiban mainte-
nance than among those receiving placebo.
Any more than minor risk or burden to the pregnant mother of
treatment for the sake of her fetus can only be justified if infant
outcomes improve. Atosiban maintenance therapy when com-
pared with placebo prolonged the interval until first recurrence of
preterm labour. Although this was statistically significant, clinical
relevance is dubious because the neonatal outcomes were very sim-
ilar in the two groups. Although the trial size was calculated with
the intention of demonstrating a difference in interval until labour
recurred, not a difference in neonatal outcomes, the absence of
even a trend towards improved infant outcomes leads the review
authors to conclude that there is insufficient evidence to support
the use of atosiban for this indication.
Outcomes of the infants born during the trial whose outcomes
are not reported could affect the results. However, their outcomes
would need to be markedly skewed between treatment groups to
affect the overall conclusions. A further minor caution is that ges-
tation at delivery is reported by infants, not by mothers. Since
progeny of multiple births inevitably deliver in very quick succes-
sion, logic suggests that multiple births should not be considered
independently when comparing gestation at delivery. However,
the proportion of multiple births in the two groups was similar (25
of 251 in the placebo group and 20 of 261 in the atosiban group),
and the distribution of gestation at delivery was sufficiently similar
that it is unlikely that re-analysis would markedly affect interpre-
tation of the study results.
The mean gestation at enrolment in the trial was approximately
31 weeks. A pharmaco-economic analysis mentioned by the au-
thors but published only in abstract form suggests that benefits of
treatment may be greater at earlier gestations (Gagnon 1998). In-
deed, after mid-third trimester preterm birth, neonatal outcomes
are sufficiently good that benefits to the infant of prolonging the
pregnancy after corticosteroid treatment and transfer to a tertiary
centre are relatively small. However, in the absence of data show-
ing greater benefits, no recommendation for atosibanmaintenance
treatment can be made at any gestation.
The intention of this review was to consider maintenance treat-
ment after threatened or actual preterm labour. Entry criteria for
the sole trial included a definition of preterm labour that included
regular contractions and documented cervical changes. It is con-
ceivable that treatment of women with less advanced changes in
the lower uterine segment and cervix would be more effective.
However, such women may also be less likely to progress to very
preterm delivery regardless of treatment. Furthermore, the num-
ber of women who delivered very prematurely in this study was
small, despite the rigour of the entry criteria.
Several systematic reviews have reported that various tocolytic
agents can postpone progression of preterm labour and delay
preterm birth for at least 48 hours, although the incidence of
neonatal morbidity andmortality was not reduced (Anotayanonth
2004; Gyetvai 1999; King 1988). However, after preterm labour
has been suppressed, the review authors have concluded thatmain-
tenance therapy using a variety of agents does not reduce the in-
cidence of preterm birth or improve neonatal outcomes (Dodd
2012; Gaunekar 2004; Han 2013; Khanprakob 2012; Nanda
2002; Sanchez-Ramos 1997). The triggering factors and mecha-
nisms of preterm birth are likely to vary between pregnancies and
preterm birth is the final common outcome of several discrete but
converging pathophysiological pathways, including ascending in-
fection, (utero) placental insufficiency, uterine distension and fetal
stress. Tocolytic agents are thought to act where these pathways
merge, when pathological influences may already be well estab-
lished. Therefore, to have a substantial influence on neonatal out-
comes, management strategies to prevent preterm birth may need
a greater focus on the underlying causes and earlier steps in the
development of preterm labour.
In this review, atosiban subcutaneously administered as mainte-
nance therapy after a period of preterm labour was not shown to
be associated with a reduction of the incidence of preterm birth,
or any improvement of neonatal outcome.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence does not support the use of oxytocin recep-
tor antagonists for maintenance therapy after a period of preterm
labour.
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Implications for research
A single large, high-quality trial of atosiban administered by con-
tinuous subcutaneous infusion as maintenance therapy after a pe-
riod of preterm labour has not shown clinically significant ben-
efits. To justify the risks and burdens of treatment for pregnant
women, any future trials using oxytocin antagonists or other drugs
as maintenance therapy for preventing preterm birth should ex-
amine a variety of important infant outcome measures, including
not only reduction of neonatal morbidity and mortality, but also
long-term infant follow-up. Future research should also focus on
the pathophysiological pathways that precede preterm labour.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Valenzuela 2000
Methods Placebo-controlled, randomised trial.
Participants 513 women in a multicentre trial who had preterm labour and intact membranes, with
pregnancies between 20 and 33 6/7 weeks, less than or equal to 3 cm cervical dilatation,
and a live fetus, who after uterine quiescence was achieved using IV atosiban (not placebo)
were randomised to either placebo or atosiban maintenance therapy
Exclusion criteria: fetal or placental abnormalities by ultrasonography, maternal indica-
tions for delivery, urinary tract infection, and overt clinical manifestations of substance
abuse
Interventions Active drug and placebo were administered at the same volume and rate.
Atosiban group: Atosiban for maintenance was administered by a subcutaneous infusion
pump to provide a continuous atosiban infusion of 6 mL/hr (30 µg/min).
Placebo group: Placebo for maintenance was administered by a subcutaneous infusion
pump to provide a continuous placebo infusion of 6 mL/hr.
If subsequent IV treatment with atosiban was given for any additional episode of
preterm labour, subcutaneous maintenance therapy using the assigned study treatment
was recommenced if uterine quiescence was achieved. Both active drug and placebo were
administered until the end of week 36 of gestation, delivery, or progression of labour
requiring a tocolytic agent other than atosiban.
All women on maintenance therapy were discharged home with daily nursing contact
for all. Compliance was checked by diaries kept by women and drugs used
Outcomes The objective of the study was to determine the safety and efficacy of maintenance
therapy with the oxytocin receptor antagonist atosiban. The primary end point was the
number of days from the
start of maintenance therapy until the first recurrence of labour
Notes A sample size of 250 women in each group was estimated to be required to provide 80%
power to detect an atosiban/placebo ratio of 1.3 for the mean numbers of days from the
start of maintenance therapy to the first recurrence of labour.
Corticosteroids were administered for standard clinical indications. GBS protocol was
unspecified
Antibiotic therapy was allowed for standard clinical conditions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation stratified
by centre, in permuted blocks of 4
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Valenzuela 2000 (Continued)
Allocation concealment (selection bias) Low risk Active drug and placebowere prepared by the R.
W. Johnson Pharmaceutical Research Institute,
Raritan,NJ: supplied to pharmacist in each cen-
tre in sequential pre-numbered envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, study personnel and monitors
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation exclusion of one woman
(placebo group) who did not receive treatment
Selective reporting (reporting bias) Unclear risk Assessment from published reports. Further in-
formation was sought from authors but was not
forthcoming
Other bias Low risk Not apparent.
hr: hour
IV: intravenous
min: minute
mL: millilitre
µg: microgram
GBS: Group B Streptococcus
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D A T A A N D A N A L Y S E S
Comparison 1. Atosiban versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 1 512 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Birth before 28 weeks 1 74 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.28, 2.01]
3 Birth before 32 weeks 1 285 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.47, 1.55]
4 Birth before 37 weeks 1 510 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.12]
5 Respiratory Distress Syndrome 1 557 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.66, 1.70]
6 Infant death (up to 12 months) 1 558 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.20, 2.74]
7 Necrotising enterocolitis 1 557 Risk Ratio (M-H, Fixed, 95% CI) 2.34 [0.46, 11.93]
8 Patent ductus arteriosius 1 557 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.47, 2.91]
9 Neonatal Intensive Care Unit
admission
1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.62, 1.14]
10 Fetal death 1 512 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 70.50]
11 Neonatal death 1 512 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.14, 2.39]
12 Perinatal death 1 512 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.21, 2.83]
13 Birth weight (grams) 1 558 Mean Difference (IV, Fixed, 95% CI) 0.10 [-131.78, 131.
98]
Analysis 1.1. Comparison 1 Atosiban versus placebo, Outcome 1 Maternal death.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 1 Maternal death
Study or subgroup Atosiban placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 0/261 0/251 Not estimable
Total (95% CI) 261 251 Not estimable
Total events: 0 (Atosiban), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
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Analysis 1.2. Comparison 1 Atosiban versus placebo, Outcome 2 Birth before 28 weeks.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 2 Birth before 28 weeks
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 7/45 6/29 100.0 % 0.75 [ 0.28, 2.01 ]
Total (95% CI) 45 29 100.0 % 0.75 [ 0.28, 2.01 ]
Total events: 7 (Atosiban), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
Analysis 1.3. Comparison 1 Atosiban versus placebo, Outcome 3 Birth before 32 weeks.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 3 Birth before 32 weeks
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 19/158 18/127 100.0 % 0.85 [ 0.47, 1.55 ]
Total (95% CI) 158 127 100.0 % 0.85 [ 0.47, 1.55 ]
Total events: 19 (Atosiban), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
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Analysis 1.4. Comparison 1 Atosiban versus placebo, Outcome 4 Birth before 37 weeks.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 4 Birth before 37 weeks
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 90/267 92/243 100.0 % 0.89 [ 0.71, 1.12 ]
Total (95% CI) 267 243 100.0 % 0.89 [ 0.71, 1.12 ]
Total events: 90 (Atosiban), 92 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
Analysis 1.5. Comparison 1 Atosiban versus placebo, Outcome 5 Respiratory Distress Syndrome.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 5 Respiratory Distress Syndrome
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 33/288 29/269 100.0 % 1.06 [ 0.66, 1.70 ]
Total (95% CI) 288 269 100.0 % 1.06 [ 0.66, 1.70 ]
Total events: 33 (Atosiban), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
16Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Atosiban versus placebo, Outcome 6 Infant death (up to 12 months).
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 6 Infant death (up to 12 months)
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 4/289 5/269 100.0 % 0.74 [ 0.20, 2.74 ]
Total (95% CI) 289 269 100.0 % 0.74 [ 0.20, 2.74 ]
Total events: 4 (Atosiban), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Maintenance Favours Placebo
Analysis 1.7. Comparison 1 Atosiban versus placebo, Outcome 7 Necrotising enterocolitis.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 7 Necrotising enterocolitis
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 5/288 2/269 100.0 % 2.34 [ 0.46, 11.93 ]
Total (95% CI) 288 269 100.0 % 2.34 [ 0.46, 11.93 ]
Total events: 5 (Atosiban), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Atosiban versus placebo, Outcome 8 Patent ductus arteriosius.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 8 Patent ductus arteriosius
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 10/288 8/269 100.0 % 1.17 [ 0.47, 2.91 ]
Total (95% CI) 288 269 100.0 % 1.17 [ 0.47, 2.91 ]
Total events: 10 (Atosiban), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Atosiban versus placebo, Outcome 9 Neonatal Intensive Care Unit admission.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 9 Neonatal Intensive Care Unit admission
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 61/284 68/266 100.0 % 0.84 [ 0.62, 1.14 ]
Total (95% CI) 284 266 100.0 % 0.84 [ 0.62, 1.14 ]
Total events: 61 (Atosiban), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Atosiban versus placebo, Outcome 10 Fetal death.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 10 Fetal death
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 1/261 0/251 100.0 % 2.89 [ 0.12, 70.50 ]
Total (95% CI) 261 251 100.0 % 2.89 [ 0.12, 70.50 ]
Total events: 1 (Atosiban), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Atosiban versus placebo, Outcome 11 Neonatal death.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 11 Neonatal death
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 3/261 5/251 100.0 % 0.58 [ 0.14, 2.39 ]
Total (95% CI) 261 251 100.0 % 0.58 [ 0.14, 2.39 ]
Total events: 3 (Atosiban), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Atosiban versus placebo, Outcome 12 Perinatal death.
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 12 Perinatal death
Study or subgroup Atosiban Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valenzuela 2000 4/261 5/251 100.0 % 0.77 [ 0.21, 2.83 ]
Total (95% CI) 261 251 100.0 % 0.77 [ 0.21, 2.83 ]
Total events: 4 (Atosiban), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Atosiban versus placebo, Outcome 13 Birth weight (grams).
Review: Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
Comparison: 1 Atosiban versus placebo
Outcome: 13 Birth weight (grams)
Study or subgroup Atosiban Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Valenzuela 2000 289 2746.9 (792.14) 269 2746.8 (796.16) 100.0 % 0.10 [ -131.78, 131.98 ]
Total (95% CI) 289 269 100.0 % 0.10 [ -131.78, 131.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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